International audienceBackground: Immune checkpoint inhibitors have been demonstrated to improve overall survival. Atypical patterns of response have been reported, including dissociated response (DR). We evaluated the prevalence of DR. Patients and methods: Patients had to have a baseline computed tomography (CT) scan and at least one follow-up CT scan and two target lesions (TLs). Three types of DR were evaluated using RECIST1.1: DR1, defined as at least one progressive and one responding TL; DR2, defined as at least one progressive and one stable TL; and DR3, defined as at least one stable and one responding TL. Results: A total of 1244 measurements of 272 TLs were performed in 100 patients. Forty-nine out of the 272 TLs (18%) had receiv...
International audienceBackground: Several studies reported improved outcomes with conventional treat...
Background: While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for...
Immunotherapy has changed the way we treat patients with varying cancer types. Despite these advance...
International audienceBackground: Immune checkpoint inhibitors have been demonstrated to improve ove...
Abstract Background Anti-programmed death 1/anti-programmed death ligand 1 (PD-1/PD-L1) combined wit...
A substantial fraction of patients demonstrate resistance to immune checkpoint inhibitors, which lim...
Immunotherapy has revolutionized the treatment of metastatic melanoma. Response to therapy can be co...
Manipulating an individual's immune system through immune checkpoint blockade is revolutionizing the...
Background The assessment of tumor size by RECIST using CT scans and MRIs is considered to be sta...
Simple Summary Immune checkpoint inhibitors (ICIs) and radiotherapy (RT) are widely used for patient...
Importance Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and...
Background Immunotherapy has improved overall survival in metastatic melanoma. Response to therapy c...
IMMUNE CHECKPOINT THERAPY AND STEREOTACTIC RADIOSURGERY FOR MELANOMA BRAIN METASTASES. Jack M. Qian,...
Background: While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for...
IntroductionBrain metastases (BM) are associated with dismal prognosis, and there is a dearth of eff...
International audienceBackground: Several studies reported improved outcomes with conventional treat...
Background: While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for...
Immunotherapy has changed the way we treat patients with varying cancer types. Despite these advance...
International audienceBackground: Immune checkpoint inhibitors have been demonstrated to improve ove...
Abstract Background Anti-programmed death 1/anti-programmed death ligand 1 (PD-1/PD-L1) combined wit...
A substantial fraction of patients demonstrate resistance to immune checkpoint inhibitors, which lim...
Immunotherapy has revolutionized the treatment of metastatic melanoma. Response to therapy can be co...
Manipulating an individual's immune system through immune checkpoint blockade is revolutionizing the...
Background The assessment of tumor size by RECIST using CT scans and MRIs is considered to be sta...
Simple Summary Immune checkpoint inhibitors (ICIs) and radiotherapy (RT) are widely used for patient...
Importance Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and...
Background Immunotherapy has improved overall survival in metastatic melanoma. Response to therapy c...
IMMUNE CHECKPOINT THERAPY AND STEREOTACTIC RADIOSURGERY FOR MELANOMA BRAIN METASTASES. Jack M. Qian,...
Background: While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for...
IntroductionBrain metastases (BM) are associated with dismal prognosis, and there is a dearth of eff...
International audienceBackground: Several studies reported improved outcomes with conventional treat...
Background: While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for...
Immunotherapy has changed the way we treat patients with varying cancer types. Despite these advance...